Table 3.
Immuno-histopathological staining and pathological diagnosis of the tumor
| Patient | c-Kit | DOG-1 | Desmin | S-100 | SMA | CD34 | ALK-1 | STAT-6 | Ki-67 | Mitosis/50 HPF | Definitive diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | − | + | nt | + | nt | nt | nt | 2% (MIB−1) | − | Leiomyoma | |
| 2 | + | + | nt | nt | nt | nt | nt | nt | 10% | 2 |
GIST EXON-9 mutation* |
| 3 | − | − | + | nt | + | nt | nt | nt | < 1% | − | Leiomyoma |
| 4 | − | − | + | nt | + | − | nt | nt | < 1% | − | Leiomyoma |
| 5 | − | − | − | − | − | − | − | − | 1–2% | 2 | Low-grade fibromyxoid sarcoma** |
| 6 | − | − | − | + | − | − | − | nt | 5% | 1 | Schwannoma** |
nt not tested
*Molecular analysis by PCR (polymerase chain reaction)
**Definitive diagnosis differs from the preoperative one